Carboplatin

Generic Name
Carboplatin
Brand Names
Paraplatin
Drug Type
Small Molecule
Chemical Formula
C6H12N2O4Pt
CAS Number
41575-94-4
Unique Ingredient Identifier
BG3F62OND5
Background

Carboplatin is an organoplatinum antineoplastic alkylating agent used in the treatment of advanced ovarian carcinoma. Early clinical studies of carboplatin were performed in 1982. Carboplatin was developed as an analog of cisplatin with reduced nephrotoxicity and vomiting.

Carboplatin was granted FDA approval on 3 March 1989.

Indication

Carboplatin is indicated in combination with an established combination of chemotherapeutic agents for the initial treatment of advanced ovarian carcinoma. Carboplatin is also indicated for the palliative treatment of ovarian carcinoma, recurrent after prior chemotherapy.

Associated Conditions
Advanced Cervical Cancer, Advanced Endometrial Cancer, Advanced Esophageal Cancers, Advanced Head and Neck Cancer, Advanced Melanoma, Advanced Non-Small Cell Lung Cancer (NSCLC), Advanced Ovarian Carcinoma, Advanced Sarcoma, Malignant Pleural Mesothelioma (MPM), Merkel Cell Carcinoma, Metastatic Breast Cancer, Refractory Hodgkin Lymphoma, Retinoblastoma, Thymoma, Advanced Bladder cancer, Advanced Small cell lung cancer, Advanced Testicular cancer, Advanced Thymoma, Refractory Non-Hodgkin's lymphoma
Associated Therapies
Conditioning regimens for allogeneic stem cell transplantation therapy
Clinical Trials
Related News

Vaccine Therapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer

Phase 2
Terminated
Conditions
Ovarian Cancer
First Posted Date
2004-04-23
Last Posted Date
2013-04-11
Lead Sponsor
Gynecologic Oncology Group
Registration Number
NCT00003386
Locations
🇺🇸

Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, United States

🇺🇸

CCOP - Atlanta Regional, Atlanta, Georgia, United States

🇺🇸

Rush-Presbyterian-St. Luke's Medical Center, Chicago, Illinois, United States

and more 57 locations

Combination Chemotherapy in Treating Patients With Bladder Cancer

Phase 3
Completed
Conditions
Urethral Cancer
Bladder Cancer
First Posted Date
2004-04-23
Last Posted Date
2023-06-15
Lead Sponsor
Eastern Cooperative Oncology Group
Target Recruit Count
490
Registration Number
NCT00003701
Locations
🇺🇸

Hahnemann University Hospital, Philadelphia, Pennsylvania, United States

🇺🇸

NYU School of Medicine's Kaplan Comprehensive Cancer Center, New York, New York, United States

🇺🇸

Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio, United States

and more 10 locations

Paclitaxel Plus Carboplatin With or Without SCH-58500 in Treating Patients With Newly Diagnosed Stage III Ovarian or Stage III Primary Peritoneal Cancer

First Posted Date
2004-04-23
Last Posted Date
2015-04-16
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
132
Registration Number
NCT00003880

S9623, Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Women With Breast Cancer

First Posted Date
2004-04-22
Last Posted Date
2013-01-24
Lead Sponsor
SWOG Cancer Research Network
Target Recruit Count
602
Registration Number
NCT00002772
Locations
🇺🇸

Memorial Sloan-Kettering Cancer Center, New York, New York, United States

Carboplatin and Gemcitabine in Treating Patients With Advanced Solid Tumors

First Posted Date
2004-04-22
Last Posted Date
2013-04-17
Lead Sponsor
Fox Chase Cancer Center
Target Recruit Count
8
Registration Number
NCT00021346
Locations
🇺🇸

Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States

Combination Chemotherapy Plus Filgrastim in Treating Patients With Stage IV Prostate Cancer That Has Not Responded to Hormone Therapy

First Posted Date
2004-04-19
Last Posted Date
2016-07-14
Lead Sponsor
Alliance for Clinical Trials in Oncology
Target Recruit Count
40
Registration Number
NCT00005810
Locations
🇺🇸

Norris Cotton Cancer Center, Lebanon, New Hampshire, United States

🇺🇸

UCSF Cancer Center and Cancer Research Institute, San Francisco, California, United States

🇺🇸

University of Chicago Cancer Research Center, Chicago, Illinois, United States

and more 4 locations

Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer That Can Not Be Surgically Removed

Phase 3
Completed
Conditions
Lung Cancer
First Posted Date
2004-04-14
Last Posted Date
2023-06-15
Lead Sponsor
Eastern Cooperative Oncology Group
Target Recruit Count
294
Registration Number
NCT00003235
Locations
🇺🇸

St. Francis Medical Center, Trenton, New Jersey, United States

🇺🇸

Trinitas Hospital - Jersey Street Campus, Elizabeth, New Jersey, United States

🇺🇸

Community Medical Center, Toms River, New Jersey, United States

and more 3 locations

Chemotherapy Plus Peripheral Stem Cell Transplantation Compared With Chemotherapy Alone in Treating Women With Stage IV Breast Cancer

Phase 2
Conditions
Breast Cancer
First Posted Date
2004-04-13
Last Posted Date
2014-01-06
Lead Sponsor
Herbert Irving Comprehensive Cancer Center
Registration Number
NCT00012311
Locations
🇺🇸

Herbert Irving Comprehensive Cancer Center, New York, New York, United States

S9914: Combination Chemotherapy Plus Filgrastim in Untreated Extensive-Stage Small Cell Lung Cancer

Phase 2
Completed
Conditions
Lung Cancer
First Posted Date
2004-04-12
Last Posted Date
2013-02-15
Lead Sponsor
SWOG Cancer Research Network
Target Recruit Count
88
Registration Number
NCT00004137
Locations
🇺🇸

USC/Norris Comprehensive Cancer Center, Los Angeles, California, United States

🇺🇸

CCOP - Central Illinois, Decatur, Illinois, United States

🇺🇸

Veterans Affairs Medical Center - Shreveport, Shreveport, Louisiana, United States

and more 82 locations

Combination Chemotherapy in Treating Patients With Previously Untreated, Newly Diagnosed Epithelial Tumors

First Posted Date
2004-04-12
Last Posted Date
2013-06-26
Lead Sponsor
Beth Israel Deaconess Medical Center
Registration Number
NCT00004082
Locations
🇺🇸

Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy